Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - alendronate sodium trihydrate 91.363mg equivalent to alendronic acid 70 mg - tablet - 70 mg - active: alendronate sodium trihydrate 91.363mg equivalent to alendronic acid 70 mg excipient: magnesium stearate maize starch microcrystalline cellulose povidone sodium starch glycolate - indicated: in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). for the treatment of osteoporosis in men to prevent fractures.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid; colecalciferol 140ug equivalent to 5600 iu;   - tablet - 70/140 - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronate anhydrous free acid colecalciferol 140ug equivalent to 5600 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid; colecalciferol 70ug equivalent to 2800 iu;   - tablet - 70/70 - active: alendronate sodium trihydrate 91.37mg equivalent to to 70 mg anhydrous free acid colecalciferol 70ug equivalent to 2800 iu   excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax plus is indicated for the treatment of osteoporosis in select patients where vitamin d supplementation is recommended.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - alendronate sodium trihydrate 13.05mg equivalent to 10 mg alendronic acid - tablet - 10 mg - active: alendronate sodium trihydrate 13.05mg equivalent to 10 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - alendronate sodium trihydrate 52.21mg equivalent to 40 mg alendronic acid - tablet - 40 mg - active: alendronate sodium trihydrate 52.21mg equivalent to 40 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - alendronate sodium trihydrate 6.53mg equivalent to 5 mg of alendronic acid - tablet - 5 mg - active: alendronate sodium trihydrate 6.53mg equivalent to 5 mg of alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid - tablet - 70 mg - active: alendronate sodium trihydrate 91.37mg equivalent to 70 mg alendronic acid excipient: croscarmellose sodium lactose magnesium stearate microcrystalline cellulose - fosamax is indicated: · in postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). · in postmenopausal women who are at risk of developing osteoporosis fosamax is indicated for the prevention of osteoporosis to reduce the risk of future fracture. · for the treatment of osteoporosis in men to prevent fractures. · for the treatment and prevention of glucocorticoid-induced osteoporosis in men, premenopausal women and postmenopausal women receiving oestrogen. · for treatment of paget's disease of bone in men and women.

ABD - İngilizce - NLM (National Library of Medicine)

jubilant cadista pharmaceuticals inc. - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 35 mg

ABD - İngilizce - NLM (National Library of Medicine)

mission pharmacal company - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronic acid 70 mg - binosto effervescent tablet 70 mg is indicated for the treatment of osteoporosis in postmenopausal women. for the treatment of osteoporosis, alendronate sodium increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies ( 14.1).] binosto is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies ( 14.2)] . the optimal duration of use has not been determined. the safety and effectiveness of binosto for the treatment of osteoporosis are based on clinical data of four years duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. binosto i

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - alendronate sodium, quantity: 10.884 mg (equivalent: alendronic acid, qty 10 mg) - tablet, uncoated - excipient ingredients: mannitol; croscarmellose sodium; purified talc; colloidal anhydrous silica; magnesium stearate - *for the treatment of osteoporosis. osteoporosis must be confirmed by: the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by the presence of osteoporotic fracture. * treatment and prevention of glucocorticoid-induced osteoporosis in post menopausal women not receiving oestrogen and who are on long term corticosteroid therapy.